• 1
    Rossant J, Nagy A 1995 Genome engineering: The new mouse genetics. Nat Med 1:592594.
  • 2
    McCauley LK 2001 Transgenic mouse models of metabolic bone disease. Curr Opin Rheumatol 13:316325.
  • 3
    Aszodi A, Bateman JF, Gustafsson E, Boot-Handford R, Fassler R 2000 Mammalian skeletogenesis and extracellular matrix: What can we learn from knockout mice? Cell Struct Funct 25:7384.
  • 4
    Priemel M, Schilling AF, Haberland M, Pogoda P, Rueger JM, Amling M 2002 Osteopenic mice: Animal models of the aging skeleton. J Musculoskel Neuron Interact 2:212218.
  • 5
    Amling M, Pogoda P, Beil FT, Schilling AF, Holzmann T, Priemel M, Blicharski D, Catala-Lehnen P, Rueger JM, Ducy P, Karsenty G 2001 Central control of bone mass: Brainstorming of the skeleton. Adv Exp Med Biol 496:8594.
  • 6
    Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB 1999 Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses. Endocrinology 140:49824987.
  • 7
    Corral DA, Amling M, Priemel M, Loyer E, Fuchs S, Ducy P, Baron R, Karsenty G 1998 Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci USA 95:1383513840.
  • 8
    Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100:197207.
  • 9
    Tseng KF, Goldstein SA 1998 Systemic over-secretion of growth hormone in transgenic mice results in a specific pattern of skeletal modeling and adaptation. J Bone Miner Res 13:706715.
  • 10
    Turner ND, Knapp JR, Byers FM, Kopchick JJ 2001 Physical and mechanical characteristics of tibias from transgenic mice expressing mutant bovine growth hormone genes. Exp Biol Med (Maywood) 226:133139.
  • 11
    Richman C, Kutilek S, Miyakoshi N, Srivastava AK, Beamer WG, Donahue LR, Rosen CJ, Wergedal JE, Baylink DJ, Mohan S 2001 Postnatal and pubertal skeletal changes contribute predominantly to the differences in peak bone density between C3H/HeJ and C57BL/6J mice. J Bone Miner Res 16:386397.
  • 12
    de Vernejoul MC 1998 Markers of bone remodelling in metabolic bone disease. Drugs Aging 12(Suppl 1):914.
  • 13
    Lochmüller EM, Jung V, Weusten A, Wehr U, Wolf E, Eckstein F 2001 Precision of high-resolution dual energy X-ray absorptiometry measurements of bone mineral status and body composition in small animal models. Eur Cells Mater 1:4351.
  • 14
    Eckstein F, Lochmuller EM, Koller B, Wehr U, Weusten A, Rambeck W, Hoeflich A, Wolf E 2002 Body composition, bone mass and microstructural analysis in GH-transgenic mice reveals that skeletal changes are specific to bone compartment and gender. Growth Horm IGF Res 12:116125.
  • 15
    Eckstein F, Pavicic T, Nedbal S, Schmidt C, Wehr U, Rambeck W, Wolf E, Hoeflich A 2002 Insulin-like growth factor-binding protein-2 (IGFBP-2) overexpression negatively regulates bone size and mass, but not density, in the absence and presence of growth hormone/IGF-I excess in transgenic mice. Anat Embryol (Berl) 206:139148.
  • 16
    Schmidt C, Priemel M, Kohler T, Weusten A, Müller R, Amling M, Eckstein F 2003 Precision and accuracy of peripheral quantitative computed tomography (pQCT) in the mouse skeleton as compared to histology and micro-computed tomography (μCT). J Bone Miner Res 18:14861496.
  • 17
    Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME, Rosenfeld MG, Birnberg NC, Evans RM 1982 Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 300:611615.
  • 18
    Wolf E, Kahnt E, Ehrlein J, Hermanns W, Brem G, Wanke R 1993 Effects of long-term elevated serum levels of growth hormone on life expectancy of mice: Lessons from transgenic animal models. Mech Ageing Dev 68:7187.
  • 19
    Brem G, Wanke R, Wolf E, Buchmuller T, Muller M, Brenig B, Hermanns W 1989 Multiple consequences of human growth hormone expression in transgenic mice. Mol Biol Med 6:531547.
  • 20
    Wolf E, Wanke R, Hermanns W, Brem G, Pirchner F, Butler-Wemken I 1991 Growth characteristics of metallothionein-human growth hormone transgenic mice as compared to mice selected for high eight-week body weight and unselected controls. I. Body weight gain and external body dimensions. Growth Dev Aging 55:225235.
  • 21
    Wolf E, Rapp K, Brem G 1991 Expression of metallothionein-human growth hormone fusion genes in transgenic mice results in disproportionate skeletal gigantism. Growth Dev Aging 55:117127.
  • 22
    Wolf E, Rapp K, Wanke R, Hermanns W, Pirchner F, Butler-Wemken I, Brem G 1991 Growth characteristics of metallothionein-human growth hormone transgenic mice as compared to mice selected for high eight-week body weight and unselected controls. II. Skeleton. Growth Dev Aging 55:237248.
  • 23
    Halse J, Melsen F, Mosekilde L 1981 Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol (Copenh) 97:1822.
  • 24
    Ho PJ, Fig LM, Barkan AL, Shapiro B 1992 Bone mineral density of the axial skeleton in acromegaly. J Nucl Med 33:16081612.
  • 25
    Kotzmann H, Bernecker P, Hubsch P, Pietschmann P, Woloszczuk W, Svoboda T, Geyer G, Luger A 1993 Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res 8:459465.
  • 26
    Jockenhovel F, Rohrbach S, Deggerich S, Reinwein D, Reiners C 1996 Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res 1:377382.
  • 27
    Kayath MJ, Vieira JG 1997 Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int 7:226230.
  • 28
    Bolanowski M, Wielgus W, Milewicz A, Marciniak R 2000 Axial bone mineral density in patients with acromegaly. Acad Radiol 7:592594.
  • 29
    Ueland T, Ebbesen EN, Thomsen JS, Mosekilde L, Brixen K, Flyvbjerg A, Bollerslev J 2002 Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Invest 32:122128.
  • 30
    Scillitani A, Battista C, Chiodini I, Carnevale V, Fusilli S, Ciccarelli E, Terzolo M, Oppizzi G, Arosio M, Gasperi M, Arnaldi G, Colao A, Baldelli R, Ghiggi MR, Gaia D, Di Somma C, Trischitta V, Liuzzi A 2003 Bone mineral density in acromegaly: The effect of gender, disease activity and gonadal status. Clin Endocrinol (Oxf) 58:725731.
  • 31
    Delmas PD 2002 Treatment of postmenopausal osteoporosis. Lancet 359:20182026.
  • 32
    Marcus R 2000 Anabolic therapies. Clin Lab Med 20:623637.
  • 33
    Rosen CJ, Bilezikian JP 2001 Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86:957964.
  • 34
    Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620625.
  • 35
    Chan JM, Stampfer MJ, Giovannucci E, Ma J, Pollak M 2000 Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: Epidemiological studies. Growth Horm IGF Res 10(Suppl A):S32S33.
  • 36
    Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:13931396.
  • 37
    Rosen CJ, Wuster C 2003 Growth hormone rising: Did we quit too quickly? J Bone Miner Res 18:406409.
  • 38
    Geusens PP, Boonen S 2002 Osteoporosis and the growth hormone-insulin-like growth factor axis. Horm Res 58(Suppl 3):4955.
  • 39
    Gillberg P, Mallmin H, Petren-Mallmin M, Ljunghall S, Nilsson AG 2002 Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 87:49004906.
  • 40
    Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA 2003 Growth hormone increases bone mineral content in postmenopausal osteoporosis: A randomized placebo-controlled trial. J Bone Miner Res 18:393405.
  • 41
    Sandstedt J, Ohlsson C, Norjavaara E, Nilsson J, Tornell J 1994 Disproportional bone growth and reduced weight gain in gonadectomized male bovine growth hormone transgenic and normal mice. Endocrinology 135:25742580.
  • 42
    Sandstedt J, Tornell J, Norjavaara E, Isaksson OG, Ohlsson C 1996 Elevated levels of growth hormone increase bone mineral content in normal young mice, but not in ovariectomized mice. Endocrinology 137:33683374.
  • 43
    Tseng KF, Bonadio JF, Stewart TA, Baker AR, Goldstein SA 1996 Local expression of human growth hormone in bone results in impaired mechanical integrity in the skeletal tissue of transgenic mice. J Orthop Res 14:598604.
  • 44
    Wolf E, Wanke R, Schenck E, Hermanns W, Brem G 1995 Effects of growth hormone overproduction on grip strength of transgenic mice. Eur J Endocrinol 133:735740.
  • 45
    Richman C, Baylink DJ, Lang K, Dony C, Mohan S 1999 Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo. Endocrinology 140:46994705.
  • 46
    Black D, Duncan A, Robins SP 1988 Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197203.
  • 47
    Colwell A, Russel RG, Eastell R 1993 Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 23:341349.
  • 48
    Kasukawa Y, Baylink DJ, Guo R, Mohan S 2003 Evidence that sensitivity to growth hormone (GH) is growth period and tissue type dependent: Studies in GH-deficient lit/lit mice. Endocrinology 144:39503957.
  • 49
    Yeh JK, Chen MM, Aloia JF 1997 Effects of estrogen and growth hormone on skeleton in the ovariectomized rat with hypophysectomy. Am J Physiol 273:E734E742.
  • 50
    Prakasam G, Yeh JK, Chen MM, Castro-Magana M, Liang CT, Aloia JF 1999 Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats. Bone 24:491497.
  • 51
    Kim BT, Mosekilde L, Duan Y, Zhang XZ, Tornvig L, Thomsen JS, Seeman E 2003 The structural and hormonal basis of sex differences in peak appendicular bone strength in rats. J Bone Miner Res 18:150155.
  • 52
    Mohan S, Richman C, Guo R, Amaar Y, Donahue LR, Wergedal J, Baylink DJ 2003 Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms. Endocrinology 144:929936.
  • 53
    Choi HK, Waxman DJ 2000 Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: Developmental regulation and role in male-specific liver gene expression. Endocrinology 141:32453255.
  • 54
    Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC 1998 Growth hormone and bone. Endocr Rev 19:5579.
  • 55
    Simpson H, Savine R, Sonksen P, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Cohen P, Hintz R, Ho K, Mullis P, Robinson I, Strasburger C, Tanaka T, Thorner M 2002 Growth hormone replacement therapy for adults: Into the new millennium. Growth Horm IGF Res 12:133.
  • 56
    Augat P, Gordon CL, Lang TF, Iida H, Genant HK 1998 Accuracy of cortical and trabecular bone measurements with peripheral quantitative computed tomography (pQCT). Phys Med Biol 43:28732883.